World Diabetes Day | From Akkermansia to Multi-Strain Innovation: Advancing Microbiome-Based Solutions for Metabolic Health

World Diabetes Day highlights the growing global burden of diabetes and metabolic disorders. Gut microbiota balance plays a key role in metabolic health, and Akkermansia muciniphila (AKK) — a “next-generation probiotic” discovered in 2004 — has emerged as a promising contributor. Studied in over 70 countries with more than 1,700 publications and 600 patents, AKK supports glucose regulation, gut barrier integrity, and inflammation control, linking gut health to metabolic and immune function. Research shows it is associated with obesity, type 2 diabetes, and non-alcoholic fatty liver disease, and may also have benefits in cancer immunotherapy, stress management, and neurological health, with both live and pasteurized forms demonstrating positive effects.

Our Research: Akkermansia muciniphila Akk11

Our team focuses on clinical potential of AKK. Using our proprietary strain Akk11, we have conducted a randomized, double-blind, placebo-controlled study (NCT06653101) showing clear benefits:

• Significant reduction in weight and body fat: Waist-to-hip ratio showed a meaningful decrease, indicating substantial reduction in visceral fat. Every 0.01 reduction in this ratio is associated with a 3-5% lower cardiovascular risk.

• Marked improvement in metabolic health: Serum GLP-1 and PYY levels increased significantly, while MDA decreased notably, demonstrating enhanced insulin sensitivity and improved antioxidant capacity.

• Meaningful benefits in mental well-being: Both depressive symptoms and sleep disturbance scores decreased substantially, supporting the role of the gut-brain axis.

Building on these findings, we are conducting further research on pasteurized Akk11 to evaluate its impact on blood glucose regulation in obese individuals (NCT06964919).

Expanding Our Pipeline: Microbiome-Based Approaches for Diabetes Management

Beyond Akk11, we are actively developing multi-strain probiotic interventions targeting different metabolic and diabetic conditions:

• Lactobacillus rhamnosus LRa05 – Under clinical evaluation for gestational diabetes mellitus (GDM) , exploring its ability to balance gut microbiota and improve glucose control (NCT06901791).

• Bifidobacterium longum BL21 – Shown to regulate glucose metabolism, significantly reducing HbA1c and fasting blood glucose (FBG) in type 2 diabetes (ChiCTR2300073299).

• WecProA (BLa80 + LRa05 + BBr60) – A multi-strain formulation that improves glycemic control and reduces inflammation in type 2 diabetes (NCT06440486).

Together, these programs reflect our integrated approach to improving metabolic health through multiple microbial pathways — moving beyond single-strain effects to deliver personalized, evidence-based solutions for diabetes care.

Redefining Metabolic Health Through Microbiome Innovation

As microbiome science advances from discovery to clinical translation, we are turning innovation into measurable health impact. Led by Akk11 and supported by BL21, LRa05, and WecProA, our growing portfolio spans multiple health domains, with metabolic regulation as a central focus.

This overview highlights the validated potential of these products to support metabolic health and contribute to diabetes management.

Our mission drives us forward: Quality Probiotics, Quality Life.
Learn more:【 http://www.wecare-life.com 】
Contact Us: 【 sales@wecare-life.com 】